XTLB
XTL Biopharmaceuticals
XTLB
XTLB
4 hedge funds and large institutions have $261K invested in XTL Biopharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$7.32K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.52K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$31.3K |
| 2 |
Morgan Stanley
New York
|
-$2.55K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $227K | – | – | – |
|
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $20K | +$7.32K | +6,307 | +58% |
|
|
3
Morgan Stanley
New York
| $12.6K | -$2.55K | -2,240 | -17% |
|
|
4
UBS Group
Zurich,
Switzerland
| $1.52K | +$1.52K | +1,336 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$31.3K | -25,211 | Closed |
|